Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A long-term phase IIIb study to evluate the safety and efficacy of OCREVUS in people with primary progressive multiple sclerosis (PPMS).

Trial Profile

A long-term phase IIIb study to evluate the safety and efficacy of OCREVUS in people with primary progressive multiple sclerosis (PPMS).

Planning
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2018

At a glance

  • Drugs Ocrelizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms ORATORIO-HAND
  • Most Recent Events

    • 12 Oct 2018 Trial design of this trial and subgroup analysis results of the ORATORIO study presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 12 Oct 2018 According to an abstract presented at 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, screening of the trial will begin Q4 2018. This study has been designed based on the subgroup analysis on upper limb function conducted in ORATORIO study.
    • 20 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top